We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+3.29%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.76B
AUM Growth
+$170M
Cap. Flow
+$156M
Cap. Flow %
5.64%
Top 10 Hldgs %
29.4%
Holding
140
New
9
Increased
43
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$48.9M
2
ADPT icon
Adaptive Biotechnologies
ADPT
+$26.6M
3
PODD icon
Insulet
PODD
+$25.1M
4
CHRS icon
Coherus Oncology
CHRS
+$21M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$14.7M

Top Sells

Rank Stock Value
1
WMGI
Wright Medical Group Inc
WMGI
+$29M
2
CVET
Covetrus, Inc. Common Stock
CVET
+$17.8M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$16.4M
4
IFRX icon
InflaRx
IFRX
+$8.5M
5
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$7.18M

Sector Composition

Rank Sector Weight
1 Healthcare 86.18%
2 Consumer Staples 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
76
AnaptysBio
ANAB
$1.68B
$12.3M 0.45%
218,500
+48,500
+29% +$3.49M
BMRN icon
77
BioMarin Pharmaceuticals
BMRN
$12.4B
$12.2M 0.44%
142,500
+7,500
+6% +$642K
AXGN icon
78
Axogen
AXGN
$2.5B
$12M 0.43%
603,970
– –
ZGNX
79
DELISTED
Zogenix, Inc.
ZGNX
$11.2M 0.41%
235,000
– –
RIGL icon
80
Rigel Pharmaceuticals
RIGL
$750M
$11M 0.4%
420,000
– –
ABBV icon
81
AbbVie
ABBV
$435B
$10.9M 0.39%
+150,000
New +$11.8M
FRPT icon
82
Freshpet
FRPT
$3.22B
$10.7M 0.39%
235,000
– –
TBPH icon
83
Theravance Biopharma
TBPH
$877M
$8.98M 0.32%
550,000
– –
AGIO icon
84
Agios Pharmaceuticals
AGIO
$1.93B
$8.51M 0.31%
170,500
+53,000
+45% +$2.83M
QTTB icon
85
Q32 Bio
QTTB
$464M
$8.32M 0.3%
23,611
+3,055
+15% +$1.2M
SRGA
86
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$8.29M 0.3%
65,000
– –
KRTX
87
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$8.28M 0.3%
+413,500
New +$8.28M
ACHN
88
DELISTED
Achillion Pharmaceuticals
ACHN
$7.91M 0.29%
2,950,000
+250,000
+9% +$738K
ASMB icon
89
Assembly Biosciences
ASMB
$529M
$7.55M 0.27%
46,667
+9,167
+24% +$1.74M
DERM
90
DELISTED
Dermira, Inc.
DERM
$7.41M 0.27%
775,000
– –
PBYI icon
91
Puma Biotechnology
PBYI
$454M
$6.79M 0.25%
534,400
+76,400
+17% +$1.76M
CBAY
92
DELISTED
Cymabay Therapeutics
CBAY
$6.44M 0.23%
900,000
+185,000
+26% +$2.09M
SPRO icon
93
Spero Therapeutics
SPRO
$73M
$6.04M 0.22%
525,000
– –
BLUE
94
DELISTED
bluebird bio
BLUE
$5.98M 0.22%
3,628
+154
+4% +$266K
MRSN
95
DELISTED
Mersana Therapeutics
MRSN
$5.67M 0.21%
56,000
– –
ELV icon
96
Elevance Health
ELV
$85.5B
$5.64M 0.2%
20,000
– –
SYRE icon
97
Spyre Therapeutics
SYRE
$9.25B
$5.48M 0.2%
32,000
– –
ARDX icon
98
Ardelyx
ARDX
$997M
$5.38M 0.19%
2,000,000
– –
CO
99
DELISTED
Global Cord Blood Corporation
CO
$5.35M 0.19%
925,000
– –
RYTM icon
100
Rhythm Pharmaceuticals
RYTM
$7.96B
$5.17M 0.19%
235,000
+18,500
+9% +$467K
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Rock Springs Capital Management held 140 positions worth $2.76B, up 6.6% from $2.59B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management deployed $156M of net new capital in Q2 2019, opening 9 new positions and adding to 43 existing holdings. Its largest new stake was Bristol-Myers Squibb: 1,050,000 shares worth $47.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Covetrus, Inc. Common Stock, an estimated $17.8M trimmed.

  • Rock Springs Capital Management's largest Q2 2019 buy was Bristol-Myers Squibb: 1,050,000 shares worth $47.6M.
  • Rock Springs Capital Management added most to Coherus Oncology in Q2 2019, an estimated $21M increase.
  • Rock Springs Capital Management's biggest Q2 2019 reduction was Covetrus, Inc. Common Stock, cutting an estimated $17.8M.
  • Rock Springs Capital Management fully exited Wright Medical Group Inc in Q2 2019, selling an estimated $29M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $2.76B portfolio in Q2 2019.
  • Rock Springs Capital Management opened 9 new positions and closed 5 in Q2 2019.
  • Rock Springs Capital Management's portfolio value rose 6.6% quarter-over-quarter to $2.76B.

Based on Rock Springs Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.